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Background: Previous studies showed that intake of yacon or some lactic acid bacteria was able to inhibit the
development of diabetes mellitus, by reducing glucose and associated symptoms, for example, the lipid profile.
Objective: The purpose of this study was to assess the consumption influence of a potential symbiotic product of
soybean and yacon extract and fermented Enterococcus faecium CRL 183 and Lactobacillus helveticus ssp jugurti 416
in reducing blood glucose and lipid levels in an animal model.
Methods: Diabetes mellitus was chemically induced by intraperitoneal administration of streptozotocin (50 mg/kg
body weight). The rats were divided into four groups (n=10): GI – non-diabetic animals that received only a
standard chow diet (negative control), GII – diabetic animals that received only chow diet (positive control),
GIII – diabetic animals that received the chow diet + 1 mL/kg body weight/day of soybean and yacon unfermented
product, GIV – diabetic rats that received the chow diet + 1 mL/kg body weight/day of soybean and yacon
fermented product. There was a seven-week treatment period and the following parameters were evaluated:
animal body weight, food and water intake, blood glucose, enzyme activities of aspartate aminotransferase (AST)
and alanine aminotransferase (ALT), triglycerides levels, total cholesterol, HDL-C, non-HDL-C. Cell viability of the
fermented product was checked weekly for a seven-week period.
Results: The product average viable population was 108-109 CFU/mL, by ensuring both the rods and cocci regular
intake. No difference was observed between the water and feed intake and body weight of groups that received
unfermented and fermented products and the untreated diabetic group. The same was observed for the blood
glucose and AST and ALT activities, while some improvement was observed for a lipid profile, represented by
reduction of triglycerides level by 15.07% and 33.50% in groups III and IV, respectively, and an increase of 23.70% in
HDL-C level for group IV.
Conclusion: The results showed that the ingestion of a potential symbiotic product was neither able to promote
improvement in some of the disease symptoms, nor reduce blood glucose. However, a positive effect on
triglycerides levels and HDL-cholesterol was observed in the groups that received the unfermented product
containing yacon extract and the fermented product with Enterococcus faecium CRL 183, as well as Lactobacillus
helveticus ssp jugurti 416 and yacon extract (symbiotic product).
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Diabetes mellitus is among the tenth leading causes of
death in western countries and, despite progress in its
clinical management, it is not yet possible to control its
lethal consequences. This disease is a chronic disorder
that affects the carbohydrates metabolism, fats and pro-
teins. The characteristic of diabetes mellitus is hypergly-
cemia, which reflects a deterioration in the use of
glucose (and hence carbohydrates in general) due to de-
fective insulin secretion or deficient response to it [1,2].
Diabetes mellitus comprises a number of common
symptoms, such as excessive thirst and hunger, weak-
ness, weight loss and rising blood glucose, resulting in
excretion of glucose in the urine [3-7]. According to
Mori et al. [8], diabetes mellitus is capable of reprodu-
cing the hepatic toxic characteristics, increasing the AST
and ALT levels in serum blood, therefore, being useful
as hepatic biomarkers.
The atherosclerosis risk is twice to three times greater
in diabetics than in non-diabetics. The absence of insulin
promotes hydrolysis of stored triglycerides in the adipo-
cytes and their presence in the circulation, and the lead-
ing to a reduction in serum levels of HDL-C [9-11].
The probiotic foods are those that contain microor-
ganisms that modulate the intestinal microbiota and aid
the functioning of the gastrointestinal tract and thus
may prevent the disease, while prebiotics are food con-
taining substances which are resistant to enzymatic
breakdown, which stimulate the proliferation or activity
of certain bacteria in the intestinal microbiota, acting as
a selective substrate in the colon. Foods that have both
probiotics and prebiotics are called synbiotics [12].
Within this context, fermented foods containing pro-
biotics and prebiotics can be important diet compo-
nents, due to their nutritional characteristics and ability
to reduce the risk of chronic diseases [13-17].
In recent decades, the yacon (Smallanthus sonchifolius),
a natural plant in the Andean region, has aroused the
interest of researchers as it provides bioactive compounds
considered important for human health [18]. In Bolivia, it
is the potato - like yacon roots are commonly consumed
by people suffering from diabetes [19]. In studies of the
fructooligosaccharides and inulin found in yacon,
lipid-lowering effects have been observed [20].
It has also been reported that some lactic acid bac-
teria affect the progression of diabetes mellitus [21-25].
These studies show that ingestion of determined lactic
acid bacteria prevents or delays the disease onset in
various experimental models of diabetes, induced by a
chemical or by diet, or genetically modified animals
(dB/dB). However, studies relating the use of lactic acid
bacteria to the development of diabetes are scarce [26].
A variety of in vitro experiments and in vivo trials have
provided experimental evidence to support the probioticroles in lowering serum cholesterol and improving lipid
profiles [27].
Considering the probable hypoglycemic effect of
yacon, the soybean health beneficial effects and the pro-
biotic lactic acid bacteria [28-32], it seemed timely and
of great interest to assess the consumption influence of
a potential synbiotic product of soybean and yacon ex-
tract and fermented with E. faecium CRL 183 and L.
helveticus ssp. jugurti 416 in reducing blood glucose and
lipid levels in a streptozotocin-induced diabetes mellitus
in rats.
Materials and methods
Animals and experimental protocol
Male wistar rats (n=40), aged 5 weeks (weight 130-
170 g), were obtained from the Central Animal Facility
of the Campus of Botucatu -UNESP, SP, Brazil. During
the 59-day experiment, the animals were kept under
controlled temperature (22°C ± 2°C), with a light–dark
cycle of 12:12 h, with free access to standard chow and
water. The product under study was administered to the
animals for seven weeks.
Rats were fed a standard chow diet (Purina®-SP, Brazil)
for a week, to acclimatize them, and then they were ran-
domly allocated to four experimental groups (n=10): GI -
non-diabetic animals that received only the chow diet
(negative control); GII - diabetic animals that received only
chow diet (positive control); GIII – diabetic animals that
received chow diet + 1 mL/kg body weight/day of soybean
and yacon extract unfermented product; GIV – diabetic
rats that received chow diet + 1 mL/kg body weight/day of
soybean and yacon extract fermented product.
The fermented product, based on aqueous extracts of
soybean and yacon, was processed at the Development
and Production Unit for Soybean Derivatives (UNI-
SOJA), Food and Nutrition Department of the School of
Pharmaceutical Sciences, UNESP in Araraquara, SP,
Brazil, by methods described by Pauly-Silveira [33], but
all the sugar was replaced by sucralose, because of the
diabetic groups condition who consumed the product.
The Foscarin soybean variety (Ribeirão Preto, SP,
Brazil) was used in the soy milk processing (raw material
of unfermented and fermented products). The hulled
grains were submitted to a heat treatment (95°C/7 min)
and led to a continuous extracting machine (Perfecta®,
Curitiba, PR, Brazil) to obtain the soy milk. The used
yacon was of yellow variety and was purchased in local
marketing. Immediately after yacon cutting, the pieces were
blanched in hot water (97°C) and citric acid was added, for
a 15-min period. Finally, the yacon was ground and filtered
to obtain the aqueous extract [33]. The bacterial inocula
consisted of 3.0% (v/v) of a 1:1 mixture of Enterococcus
faecium CRL 183 (probiotic microorganism from
CERELA - Argentina) and Lactobacillus helveticus
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of Food Technology - ITAL - Campinas, SP, Brazil).
The aqueous extracts mixed at soybean rates: yacon
of 60.00% to 25.86% [33]. The fermentation was con-
ducted at temperatures of 37°C until the pH of 4.5
was reached. The unfermented and fermented pro-
ducts showed the following proximal composition
(%): moisture 82.85; total solids 17.15; protein 3.97;
fat 2.49; ash 0.51; carbohydrates 10.19.
The unfermented product was prepared by chemical
acidification of the synbiotic product base mixture (with-
out bacterial culture) with food-grade lactic acid (Purac,
Sao Paulo, Brazil), to reach the same pH as the fermen-
ted product (4.4 - 4.6).
After the period of adaptation, the rats were fasted for
12 h. Afterwards, the rat group II; then, the groups III
and IV by injections (intraperitoneal) of 50 mg per kg
body weight of streptozotocin (STZ) (Sigma Aldrich®,
St Louis, MO, USA) [34,35] dissolved in 10 mM citrate
buffer (pH 4·5), while animals of group I received a similar
buffer injection. Three days later, the blood glucose level
of STZ-treated rats had risen to 500 mg/dL, while group I
remained around 120 mg/dL.
The unfermented and fermented administration pro-
ducts started after confirmation of diabetes induction.
The products were administrated to the animals by gav-
age of 1 mL/kg body weight once every day, to ensure a
minimal intake of 107 CFU/day of E.faecium and of
L.helveticus ssp jugurti, in the fermented products for a
seven-week period. The fermented product contained
108- 109 CFU/mL of each microorganism.
The experimental design received approval from the
Research Ethics Committee of the School of Pharma-
ceutical Sciences, UNESP in Araraquara, SP, Brazil
(protocol CEP/FCF no. 21/2010)Measurement of total fructans
The total fructan content was measured in triplicate by a
spectrophotometric method and was carried out in yacon
extract, in the unfermented and potential synbiotic pro-
ducts (Amersham Biosciences® model Ultrospec 3100 pro,
USA) using the Megazyme Fructan HK Assay kit (AOAC
Method 999.03 and AACC Method 32.32; Megazyme
International Ireland Ltd., Wicklow, Ireland) [36].Body weight, food and water intake
The body weight of each animal was recorded weekly
throughout the experimental period.
The feed and water intakes of each animal were deter-
mined by weight difference between chow offered and
orts and the difference between the amounts of water
offered from remaining bottles, respectively, and
recorded daily throughout the experimental period.Sample collection
Blood samples were collected from a small longitudinal
incision made at the animal tail end [37].
Glycemia
The level of glucose in the plasma was assessed at the
beginning of the experiment, three days after induction
of diabetes, to verify the diabetic state, 14 days after
proof of the diabetic state and at the end of the experi-
ment, after the final administration of the products,
using Labtest Diagnostic® Kit SA (Lagoa Santa, MG,
Brazil) [38,39].
Liver enzymes (aspartate aminotransferase and alanine
aminotransferase)
The enzymatic activity of the transaminases AST and
ALT was determined in the plasma by Labtest Diagnos-
tic® Kit SA (Lagoa Santa, MG, Brazil), at the same time
as the glucose analysis [38,39].
Serum lipids
Lipids were determined in the plasma, by using Labtest
Diagnostic® Kit SA (Lagoa Santa, MG, Brazil) [38,39].
nHDL-C was calculated by the equation: nHDL-C=Total
Cholesterol – HDL-C [40].
Euthanasia of animals
All experimental animals were decapitated by guillotine at
the end of the experiment (after seven weeks of treatment).
Statistical analysis
Results are presented as mean ± standard deviation.
One-way ANOVA was used to determine a significant
difference between groups (p < 0.05) and Tukey's test to
perform multiple comparisons between means.
Results
Content of total fructans
The total concentration of fructans found in the aqueous
yacon extract was 7.96 g/100 g; 4.32 g/100 g in the un-
fermented product and 4.30 g/100 g in the symbiotic
product. The concentrations of unfermented and synbio-
tic product did not show statistical difference (p < 0.05),
suggesting that the microorganisms used in fermentation
process were not able to modify the total fructans level.
Body weight, feed and water intake
Table 1 shows the average consumption of water and feed
as well as change in body weight throughout the experi-
mental period; the evident increase in hunger and thirst in
groups II, III and IV confirmed the induction of diabetes.
It is observed that for the three variables presented in
Table 1, the diabetic control group (II) did not differ sta-
tistically from the other diabetic groups (III and IV). The
Table 1 Average daily intakes of water and feed and body weight of animals in non-diabetic and diabetic groups
during the trial period
Groups Group I Group II Group III Group IV
Parameters
Water consumption (mL) 41.26b ± 0.81 173.45a ± 10.63 192.16a ± 9.20 183.46a ± 9.16
Feed consumption (g) 25.47b ± 0.26 38.89a ± 1.20 39.56a ± 1.41 38.78a ± 1.31
Body weight (g) 306.47b ± 24.33 242.41a ± 8.10 245.49a ± 8.23 235.29a ± 6.93
Values are expressed as mean ± standard error (n=10). Means values for groups with same lowercase letter on the same line do not differ significantly at p ≤ 0.05.
Group I = non-diabetic animals that received only chow diet (negative control), Group II = diabetic animals that received only chow diet (positive control), Group
III = diabetic animals that received chow diet + 1 mL/kg bw/day of soybean and yacon unfermented product, Group IV = diabetic animals that received chow diet
+ 1 mL/kg bw/day of soybean and yacon fermented product.
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betic rats and their weight was lower than for non-
diabetic rats.Glycemia
In Table 2 there are the results about glucose levels.Liver enzymes
The AST and ALT serum levels were presented in
Table 3.
Regarding the enzyme alanine aminotransferase (ALT),
there were significant differences among group I and the
others, starting from time T2. Note also that all diabetic
groups showed a significant increase in ALT activity after
seven weeks of treatment, but noting that, once again,
groups II, III and IV did not differ significantly from
each other.Serum lipids
Table 4 shows the values of the lipid profile of the four
groups throughout the experimental period.
It is observed that, at the end of the experiment, trigly-
cerides levels were lower in the groups receiving treat-
ment (III and IV) than in the positive control (group II),
although these levels are higher than that observed in
group I.Table 2 Plasma glucose levels of groups of non-diabetic and
Groups Group I Group II
Time
Glucose
T0 117.20B.a ± 2.22 119.10C.a ± 2.60
T1 129.20AB.b ± 3.71 503.14B.a ± 25.1
T2 103.36C.b ± 3.97 633.00A.a ± 29.4
T3 134.46A.b ± 2.41 538.60B.a ± 14.0
Values are expressed in mg/dL (n=10, mean ± standard error). Means values for gro
0.05; comparing times, means with same capital letters in the same column do not
chow diet (negative control), Group II = diabetic animals that received only chow d
1 mL/kg bw/day of soybean and yacon unfermented product, Group IV = diabetic a
unfermented product. T0 = initial blood collection, T1 = blood collection after a we
weeks to detect any reversal of the diabetic condition, T3 = blood collection whenAs for total cholesterol, it is clear that at the end of
the experiment (T3), groups II, III and IV did not differ,
while they were significantly different from group I.
Regarding HDL-C at the end of the experiment (T3),
group IV, which consumed the potential symbiotic prod-
uct, differed from all the other groups, with the highest
value for this parameter. On the other hand, there was
no statistical difference in non HDL-C among any of the
groups during the experiment.Discussion
The fructans content, determined in the unfermented and
symbiotic product, was found to be compatible with recom-
mended daily intake of prebiotics (4-5 g/day) to stimulate
the growth of Bifidobacterium [41], while doses of 3 to
10 g/day promote reduction of blood pressure, have a bene-
ficial effect on lipid metabolism, improve gastrointestinal
health [42] and provide hypoglycemic effect [43]. Although
a high content of fructans in the unfermented and symbi-
otic products was found, a hypoglycemic effect was not
observed, but it may have been one of the factors that con-
tributed to reducing the triglycerides in groups III and IV.
In addition, some studies suggest that caffeic acid, chloro-
genic acid (3-caffeoylquinic acid) and very probably other
caffeic acid derivatives, such as 3,4-dicaffeoylquinic, 3,5-
dicaffeoylquinic and 4,5-dicaffeoylquinic acids, are also thediabetic animals during the trial period
Group III Group IV
121.00C.a ± 1.78 125.40C.a ± 2.36
7 504.67B.a ± 22.68 534.50B.a ± 21.02
3 657.57A.a ± 11.31 652.67 A.a ± 9.60
5 551.29B.a ± 12.97 554.33B.a ± 12.84
ups with lowercase letters on the same line do not differ significantly at p ≤
differ significantly p ≤ 0.05. Group I = non-diabetic animals that received only
iet (positive control), Group III = diabetic animals that received chow diet +
nimals that received chow diet + 1 mL/kg bw/day of soybean and yacon
ek to confirm the induction of diabetes mellitus, T2 = blood collection four
sacrificed at end of experiment (7 weeks).
Table 3 Concentrations of liver enzymes in non-diabetic and diabetic groups during the trial period




T0 164.18B.a ± 7.48 168.78B.a ± 9.55 163.45A.a ± 7.72 159.00B.a ± 10.22
T1 156.50B.a ± 9.33 159.75B.a ± 15.15 180.10A.a ± 11.90 175.7AB.a ± 12.64
T2 208.09A.a ± 8.24 283.90A.a ± 35.68 219.36A.a ± 14.85 254.20A.a ± 29.05
T3 150.45B.a ± 9.20 166.56B.a ± 29.97 171.64A.a ± 25.03 164.25B.a ± 16.97
ALT
T0 74.60AB.a ± 3.49 78.25B.a ± 2.59 73.18B.a ± 2.98 67.50C.a ± 1.57
T1 63.10C.a ± 2.25 67.5B.a ± 1.88 61.46B.a ± 1.87 59.25C.a ± 2.43
T2 68.90B.b ± 1.75 126.80A.a ± 18.05 151.63A.a ± 10.80 136.80B.a ± 12.38
T3 83.80A.b ± 2.61 150.00A.a ± 9.25 163.00A.a ± 12.85 163.83A.a ± 5.50
Values are expressed in U/L (n=10, mean ± standard error). Comparisons between groups: mean values with the same lowercase letter on the same line do not
differ significantly at p ≤ 0.05, and times: equal means with capital letters in the same column do not differ significantly p ≤ 0.05. Group I = non-diabetic animals
that received only chow diet (negative control), Group II = diabetic animals that received only chow diet (positive control), Group III = diabetic animals that
received chow diet + 1 mL/kg bw/day of soybean and yacon unfermented product, Group IV = diabetic animals that received chow diet + 1 mL/kg bw/day
of soybean and yacon unfermented product. T0 = initial blood collection, T1 = blood collection after a week to confirm the induction of diabetes mellitus,
T2 = blood collection after four weeks to detected any reversal of the diabetic state, T3 = blood collection when sacrificed at end of experiment (seven weeks).
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leaves [44,45].
The highest feed intake observed in the diabetic
groups can be explained by the absence of circulating
insulin, which causes a deficiency in glucose transport,Table 4 Lipid profile in non-diabetic and diabetic groups dur




T0 135.10B.a ± 12.62 173.73B.a
T2 188.82A.b ± 12.90 425.33AB.a
T3 149.55AB.c ± 9.95 628.67A.a
Total cholesterol
T0 101.37A.a ± 4.66 111.73 A.a
T2 80.78B.b ± 3.30 100.79A.a
T3 69.82B.b ± 5.52 96.78A.a
HDL-C
T0 45.27A.a ± 1.92 55.82A.a
T2 43.82A.a ± 2.59 52.40 A.a
T3 34.37B.c ± 2.13 52.44A.b
nHDL-C
T0 39.56B.a ± 2.35 48.57A.a
T2 35.46B.a ± 4.19 48.13A.a
T3 56.09A.a ± 3.60 55.91A.a
Values are expressed in mg/dL (n=10, mean ± standard error). Means values for gro
0.05; comparing times, means with same capital letters in the same column do not
chow diet (negative control), Group II = diabetic animals that received only chow d
1 mL/kg bw/day of soybean and yacon unfermented product, Group IV = diabetic a
unfermented product. T0 = initial blood collection, T2 = blood collection after four
when sacrificed at end of experiment (seven weeks).leading to a deficiency of energy in the cells, resulting
in increased feeding to compensate for that lack of
energy [46].
In addition, it can be explained by physiological pro-
cesses related to the pathology, such as hyperglycemia,ing the trial period
p II Group III Group IV
± 11.46 156.64B.a ± 12.51 175.36C.a ± 13.37
± 84.89 396.18A.a ± 49.70 348.50AB.a ± 31.14
± 32.05 503.25A.b ± 25.79 419.00A.b ± 35.39
± 3.33 99.64A.a ± 2.81 98.9A.a ± 2.71
± 4.97 102.46A.a ± 3.73 100.25A.a ± 4.07
± 5.61 97.64A.a ± 2.96 90.33A.a ± 4.84
± 3.64 50.09A.a ± 1.66 52.82A.a ± 3.25
± 2.20 48.64A.a ± 1.50 48.70A.a ± 2.25
± 1.70 52.27A.b ± 1.61 65.00A.a ± 6.36
± 2.81 48.63A.a ± 2.15 45.50A.a ± 3.01
± 3.93 45.37A.a ± 2.66 39.40A.a ± 2.16
± 3.88 49.55A.a ± 2.92 46.09 A.a ± 3.19
ups with lowercase letters on the same line do not differ significantly at p ≤
differ significantly p ≤ 0.05. Group I = non-diabetic animals that received only
iet (positive control), Group III = diabetic animals that received chow diet +
nimals that received chow diet + 1 mL/kg bw/day of soybean and yacon
weeks to detect any reversal of the diabetic condition, T3 = blood collection
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the catabolic processes involved in diabetes mellitus [47].
While in the non-diabetic group (group 1), the animals
appeared, throughout the experiment, in good general
condition, with normal appetite, progressive weight gain
and maintenance of water intake, food intake and diur-
esis, the diabetic animals had a strong odor of urine and
functional changes, such as polyuria and polydipsia.
However, there were no significant changes of the coat
or apathy, as described by Passos and Park [48].
In the present study, the increased serum glucose
levels in groups II, III and IV confirmed that the STZ
was effective in inducing diabetes mellitus, values of
around 120 mg/dL rising to nearly 500 mg/dL, a level
correlated with severe experimental diabetes [49].
In the blood tests used to check for induction reversal
(T2), the highest blood glucose levels were recorded,
thus confirming the absence of reversion. The rate of in-
duction was 100%, since long-term diabetes mellitus was
found in all animals, as observed by Rakieten et al. [50],
in rats and dogs, at the same doses of 50 mg STZ per kg
body weight.
At T0, there was no statistical difference in glycemic
level among the groups. After induction and until the
end of the experiment, only group I (non-diabetic) main-
tained low values, by significantly differing from the
other groups, which all had become diabetic.
Although a reduction in blood glucose occurred at the
end of the experiment, it cannot be suggested that, thus
revealed a tendency for diabetes to stabilize, owing to
the presence of yacon and/or probiotic bacteria, since
the animals in group II received only water and feed and
showed the same reduction. Studies by Maffezzoli [51]
showed results similar to those in this study.
The organism itself tends to normalize high blood glu-
cose levels by three main routes: stimulating glucose up-
take by peripheral tissues (muscle and adipose tissue);
altering the insulin metabolism (by reducing the degrad-
ation of insulin in the liver or stimulating insulin secre-
tion) and, finally, by inhibiting the reabsorption of glucose
by the kidneys, resulting in the elimination of glucose in
the urine [52].
The glycemic control observed in animal studies and early
studies in humans has indicated that ingested fructooligosac-
charides probably act to stimulate glucose utilization in per-
ipheral tissues (muscle and adipose tissue) [52].
The enzymes analyzed in this study are markers of
liver injury; the observed increase in AST and ALT activ-
ity indicates an aggressive hepatocyte injury [53] with re-
gard to these enzymes, it was noted that there was no
significant difference among the three diabetic groups,
indicating again that the presence of yacon extract did
not improve the condition of the liver of animals in
groups III and IV.A study by Baroni et al. [54] evaluated the activity of
AST and ALT in the plasma of diabetic and non-diabetic
animals that received 10% hydroethanolic extract of
yacon for 14 days. These researchers observed that the
activity of these enzymes increased in diabetic rats but
that, on administration of the extract, the enzyme acti-
vities of diabetic rats were close to those of control
animals. One possible explanation is that the administra-
tion of the yacon extract may have decreased the hepatic
lesions caused by the disease. However, these results
were not confirmed in our study.
Regarding the lipid profile, it was observed that at the
end of the experiment, triglycerides levels were lower in
groups III and IV than in group II, although all these
levels were higher than that observed in group I, indicat-
ing that both the unfermented and fermented products
may have reduced this serum lipid in STZ-induced ani-
mals. Numerically, group IV had the lowest triglycerides,
which may be related to the aqueous yacon extract [55]
and the probiotic one [56] used in the synbiotic product.
Whereas diabetes results in increased lipolysis in adi-
pose tissue, leading to higher blood levels of fatty acids,
there is also a greater production of ketone bodies by the
liver. However, the excess fatty acid captured by the liver
is not fully oxidized to ketone bodies by ketogenesis. Thus,
these excess fatty acids are directed to the synthesis of tri-
glycerides, which is converted into VLDL. As VLDLs in
excess are not be fully metabolized by lipoprotein lipase, a
state of a hypertriglyceridemia would occur [57].
As for total cholesterol, note that at the end of the ex-
periment groups II, III and IV did not differ, although they
were significantly different from group I. However, group
IV again showed, numerically, the lowest value for this
parameter, although not statistically different from the
others; that may be an indicative of a tendency, in agree-
ment with the results observed by Rossi et al. [58], which
showed that E. faecium CRL 183 was able to reduce total
cholesterol levels by 18.4% in hyperlipidemic rabbits.
A variety of past in vitro experiments and in vivo trials
have provided evidence to support the roles of probiotics in
lowering serum cholesterol and improving lipid profiles.
Several mechanisms of cholesterol reduction by pro-
biotics via control of cholesterol metabolism have been
proposed. One such mechanism is the removal of chol-
esterol by assimilation. The assimilation of cholesterol
by probiotics in the small intestine could reduce serum
cholesterol by reducing the absorption of cholesterol in
the intestines [59]. Probiotics must be viable and grow-
ing, in order to be able to remove or assimilate choles-
terol [60]. Other researchers have suggested that the
incorporation of cholesterol into cell membranes could
be another mechanism used to reduce cholesterol in
media, or that it involves the ability of certain probiotics
to deconjugate bile acids enzymatically [61].
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group IV (symbiotic) differed from the other groups,
with the highest value for this parameter, which may be
due to the presence of E. faecium CRL 183. This ability
of E. faecium CRL 183 to promotion increase in HDL-C
has been observed in a study by Rossi et al. [58], where
the authors showed an increase of this fraction by 17.8%.
In comparison to the results of Khamisy [62], who
administered a suspension of Bifidobacterium and
Lactobacillus acidophilus, separately or in combination
to diabetic albino rats, the presented results were more
satisfactory in terms of the increase in HDL-C in group
IV, which received the symbiotic product; this is an
important condition in reducing the risk of onset of
coronary heart disease in diabetics.
In another study conducted by Manzoni et al. [17],
concerning the beneficial effects on rat serum lipid
effects of soy yogurt fermented with E. faecium CRL
183, only HDL levels were changed positively, by show-
ing a 46% increase.
Research indicates that the hypocholesterolemic action
of probiotics may be enhanced by the use of a prebiotic
[63]. The effects of probiotic combinations and certain
prebiotics i.e. symbiotic on blood lipids were investi-
gated by Kiebling et al. [64] and Greany et al. [65]. One
study reported that the ingestion of yogurt fermented
with L. acidophilus 145 and B. longum 913 plus 1% oli-
gofructose [64] raised the level of HDL-C, while another,
which tested the combination L. acidophilus DDS-1,
B. longum UABL-14 and fructooligosaccharides, found
no effect [65].
Regarding the fraction nHDL-C, no statistical differ-
ence was observed among the 4 groups during the ex-
perimental period.
Conclusion
The product based on aqueous extracts of yacon and
soybean fermented or not with Enterococcus faecium
CRL 183 and Lactobacillus helveticus ssp jugurti 416,
showed no positive effect on blood glucose levels, but
was effective in reducing triglycerides both unfermented
and symbiotic products and increasing HDL-cholesterol
(symbiotic product alone).
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